KR102019911B1 - 질병 및 장애 치료용 펩타이드 유사체 - Google Patents

질병 및 장애 치료용 펩타이드 유사체 Download PDF

Info

Publication number
KR102019911B1
KR102019911B1 KR1020147014281A KR20147014281A KR102019911B1 KR 102019911 B1 KR102019911 B1 KR 102019911B1 KR 1020147014281 A KR1020147014281 A KR 1020147014281A KR 20147014281 A KR20147014281 A KR 20147014281A KR 102019911 B1 KR102019911 B1 KR 102019911B1
Authority
KR
South Korea
Prior art keywords
oral
seq
peptide
delete delete
sct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147014281A
Other languages
English (en)
Korean (ko)
Other versions
KR20140093967A (ko
Inventor
노저 엠. 메타
윌리엄 스턴
모르텐 아세르 카르스달
김 헨릭센
에이미 엠. 스튜머
Original Assignee
키바이오사이언스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키바이오사이언스 아게 filed Critical 키바이오사이언스 아게
Publication of KR20140093967A publication Critical patent/KR20140093967A/ko
Application granted granted Critical
Publication of KR102019911B1 publication Critical patent/KR102019911B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020147014281A 2011-11-02 2012-11-02 질병 및 장애 치료용 펩타이드 유사체 Expired - Fee Related KR102019911B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US61/554,771 2011-11-02
US201161578620P 2011-12-21 2011-12-21
US61/578,620 2011-12-21
US13/667,578 2012-11-02
PCT/US2012/063332 WO2013067357A1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders
US13/667,578 US9006172B2 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Publications (2)

Publication Number Publication Date
KR20140093967A KR20140093967A (ko) 2014-07-29
KR102019911B1 true KR102019911B1 (ko) 2019-09-09

Family

ID=48192827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014281A Expired - Fee Related KR102019911B1 (ko) 2011-11-02 2012-11-02 질병 및 장애 치료용 펩타이드 유사체

Country Status (10)

Country Link
US (1) US9006172B2 (enExample)
JP (3) JP6170933B2 (enExample)
KR (1) KR102019911B1 (enExample)
CN (1) CN103998052B (enExample)
AU (2) AU2012332265B2 (enExample)
BR (1) BR112014010701A2 (enExample)
CA (1) CA2854175A1 (enExample)
MX (1) MX351092B (enExample)
RU (1) RU2616511C2 (enExample)
WO (1) WO2013067357A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
JP6639389B2 (ja) * 2013-11-14 2020-02-05 キーバイオサイエンス・アクチエンゲゼルシャフト 疾患および障害を処置するためのカルシトニン模倣体
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
US11420525B2 (en) 2020-04-21 2022-08-23 Mac LTT, Inc. Tractor trailer with included battery charging
US11634095B2 (en) 2020-04-21 2023-04-25 Mac LTT, Inc. Removable safety bar for creating a remote safety visual device
US12415457B2 (en) 2020-04-21 2025-09-16 Mac LTT, Inc. Safety zone with breakaway for use on a tanker truck

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764589A (en) 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
WO2010085700A2 (en) 2009-01-22 2010-07-29 Unigene Laboratories Inc. Treatment for obesity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033478B2 (ja) * 1980-06-20 1985-08-02 帝国臓器製薬株式会社 ペプチドの製造方法
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4659804A (en) * 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
JPH083196A (ja) 1994-06-21 1996-01-09 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン誘導体及びその用途
EP0726075A1 (en) 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
US5962270A (en) * 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6103495A (en) 1997-04-16 2000-08-15 Unigene Laboratories, Inc. Direct expression of peptides into culture media
CN1105726C (zh) * 1998-05-15 2003-04-16 中国科学院上海生物化学研究所 人降钙素类似物
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
JP2000290295A (ja) 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
GB0109438D0 (en) * 2001-04-17 2001-06-06 Isis Innovation Peptides
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
BRPI0412265A (pt) 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2345113T3 (es) 2004-02-11 2010-09-15 Amylin Pharmaceuticals, Inc. Peptidos de la familia amilina y metodos para su obtencion y utilizacion.
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2007002532A2 (en) 2005-06-24 2007-01-04 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN102369018B (zh) * 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764589A (en) 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
WO2010085700A2 (en) 2009-01-22 2010-07-29 Unigene Laboratories Inc. Treatment for obesity
US20100311650A1 (en) * 2009-01-22 2010-12-09 Unigene Laboratories Inc. Treatment for obesity

Also Published As

Publication number Publication date
JP6170933B2 (ja) 2017-07-26
AU2012332265A1 (en) 2014-06-05
NZ625215A (en) 2016-04-29
RU2014122171A (ru) 2015-12-10
JP2014532722A (ja) 2014-12-08
JP2017061500A (ja) 2017-03-30
AU2012332265B2 (en) 2016-11-10
CN103998052A (zh) 2014-08-20
WO2013067357A1 (en) 2013-05-10
AU2016247189B2 (en) 2017-09-14
KR20140093967A (ko) 2014-07-29
CN103998052B (zh) 2016-08-17
JP6330013B2 (ja) 2018-05-23
AU2016247189A1 (en) 2016-11-10
CA2854175A1 (en) 2013-05-10
BR112014010701A2 (pt) 2020-06-23
RU2616511C2 (ru) 2017-04-17
JP6547034B2 (ja) 2019-07-17
JP2018135360A (ja) 2018-08-30
US20130183385A1 (en) 2013-07-18
US9006172B2 (en) 2015-04-14
MX351092B (es) 2017-10-02
MX2014005265A (es) 2014-10-13

Similar Documents

Publication Publication Date Title
KR102019911B1 (ko) 질병 및 장애 치료용 펩타이드 유사체
EP3068796B1 (en) Calcitonin mimetics for treating diseases and disorders
AU2019323697B2 (en) Acylated calcitonin mimetics
US10239929B2 (en) Peptide analogs for treating diseases and disorders
EP2773365B1 (en) Peptide analogs for treating diseases and disorders
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2018172390A1 (en) Calcitonin mimetics for treating diseases and disorders
WO2020039052A1 (en) Calcitonin mimetics for treating diseases and disorders
NZ625215B2 (en) Peptide analogs for treating diseases and disorders
HK1247623B (en) Calcitonin mimetics for treating diseases and disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220904

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220904

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000